#USA #Kahn Swick & Foti #New Orleans #Corcept Therapeutics #FDA Approval Issues

Corcept Therapeutics Faces Class Action Lawsuit Amid FDA Approval Issues

Corcept Therapeutics Incorporated has found itself embroiled in a class action lawsuit as a consequence of recent FDA approval troubles, which have led to a staggering 50% decline in its stock price. The legal proceedings stem from allegations that Corcept failed to adequately inform investors about the risks related to its lead product candidate, relacorilant, during a key period.

Overview of the Lawsuit

On March 27, 2026, Kahn Swick & Foti, LLC (KSF) announced that investors who suffered significant losses have until April 21, 2026, to file applications to be considered as lead plaintiffs in the lawsuit. This case is set to take place in the United States District Court for the Northern District of California. The focus is on shares acquired between October 31, 2024, and December 30, 2025.

The lawsuit claims that Corcept and several executives did not disclose vital information that would have influenced investors' decisions. During the designated class period, Corcept asserted to its investors that the likelihood of approval for relacorilant from the FDA was high after the submission of its New Drug Application (NDA). This affirmation raised optimism among shareholders about the company's financial future.

However, the scenario took a dramatic turn on December 31, 2025, when Corcept revealed that the FDA had issued a Complete Response Letter (CRL) concerning the NDA for relacorilant, indicating the need for additional evidence of the product’s effectiveness before approval could be granted. Following this announcement, Corcept's stock price plummeted from a closing price of $70.20 on December 30 to just $34.80 the next day, a drop of over 50%.

Implications for Investors

Investors who acquired shares during this period are advised to evaluate their options carefully, particularly with regards to participating in the class action. Those who wish to join the action or seek further information are encouraged to contact Lewis Kahn, the Managing Partner of KSF, at a toll-free number provided in the announcement. It’s an opportunity for those affected to potentially recover some of their losses stemming from this corporate disclosure failure.

Background on Kahn Swick & Foti LLC

Kahn Swick & Foti, known for their expertise in securities litigation, has established a reputable standing in helping investors recover losses due to corporate malfeasance. Partnered with former Louisiana Attorney General Charles C. Foti, Jr., the firm represents a diverse clientele, ranging from institutional to retail investors. Recently recognized as one of the top firms nationally by SCAS in terms of settlement value, KSF continues to work diligently for its clients in financial recovery efforts.

For those who experienced significant losses in their investments in Corcept Therapeutics, this lawsuit presents a possible avenue for recourse. However, interested parties must act before the April 21 deadline to ensure their voices are heard in this significant case.